ArticleAntimicrobial agents and chemotherapy2014
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.Sexually transmitted diseases · 2019Trial
- Antimicrobial resistance crisis in STIs: Gonorrhea andNew microbes and new infections · 2026Review
- The Role of Antimicrobial Susceptibility and Resistance Testing forOpen forum infectious diseases · 2026Article
- Treatment Approaches for RefractoryOpen forum infectious diseases · 2026Article
- Novel features ofMicrobial genomics · 2026Article
- New Trends in Sexually Transmitted Infections Among Adolescents and Young People: Epidemiology, Clinical and Diagnostic Management.Microorganisms · 2025Review
- Phenotypic antibiotic resistance of Mycoplasma genitalium and its variation between different macrolide resistance-associated mutations.The Journal of antimicrobial chemotherapy · 2025Article
- Antimicrobial treatment and resistance in sexually transmitted bacterial infections.Nature reviews. Microbiology · 2024Review
- Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea,The Lancet regional health. Europe · 2023Review
- Review
- Impact of 16S rRNA Single Nucleotide Polymorphisms on Mycoplasma genitalium Organism Load with Doxycycline Treatment.Antimicrobial agents and chemotherapy · 2022Article
- Azithromycin and Doxycycline Resistance Profiles of U.S. Mycoplasma genitalium Strains and Their Association with Treatment Outcomes.Journal of clinical microbiology · 2021Article
- Integrating the Human and Animal Sides of Mycoplasmas Resistance to Antimicrobials.Antibiotics (Basel, Switzerland) · 2021Review
- Evidence of Horizontal Gene Transfer of 50S Ribosomal GenesFrontiers in microbiology · 2021Article
- Antimicrobial resistance inSexually transmitted infections · 2020Article
- Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.The Lancet. Infectious diseases · 2020Review
- Levels ofJournal of clinical microbiology · 2019Article
- Macrolide-resistant Mycoplasma genitalium infections in Cuban patients: an underestimated health problem.BMC infectious diseases · 2018Article
- Potency of Solithromycin against Fast- and Slow-Growing Chlamydial Organisms.Antimicrobial agents and chemotherapy · 2018Article
- Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection.Emerging infectious diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma genitalium has become well established as an etiological agent of sexually transmitted infections, but due to its fastidious growth requirements, only a few M. genitalium strains are available to determine the MICs of currently used and new antimicrobial agents. Recent clinical trials have suggested that treatment with azithromycin has decreasing efficacy due to an increasing prevalence of macrolide resistance, and alternative treatment with moxifloxacin is similarly under pressure from emerging resistance. Thus, there is an urgent need for new antimicrobials. The in vitro activity of the newly developed fluoroketolide solithromycin (CEM-101) was evaluated against a collection of 40 M. genitalium strains, including 15 with high-level macrolide resistance and 5 multidrug-resistant strains with resistance to both macrolides and quinolones. Furthermore, the MIC of solithromycin was correlated with mutations in the 23S rRNA gene and in the genes encoding ribosomal proteins L4 and L22. The in vitro results showed that solithromycin has activity against M. genitalium superior to that of other macrolides, doxycycline, and fluoroquinolones. Accordingly, this new fluoroketolide might be an effective option for treatment of M. genitalium infections. However, the efficacy of solithromycin in clinical trials with follow-up for test of cure and detection of genotypic and phenotypic resistance needs to be evaluated prior to widespread use. In a phase 2 clinical trial, solithromycin was highly effective as a single oral dose against C. trachomatis and Neisseria gonorrhoeae, suggesting that solithromycin could be a treatment option for several sexually transmitted infections, including in syndromic treatment of urethral and vaginal discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.